The effect of tumor necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: a retrospective study

References

• Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Identification and management of psoriasis and associated comorbidity (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol. 2013;133:377–85.
   PubMed Web of Science ®Google Scholar
• Al-Mutairi N, Farag AS, Al-Mutairi A. Comorbidities associated with psoriasis: an experience from the Middle East. J Dermatol. 2010;37:146–55.
   PubMed Web of Science ®Google Scholar
• Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg. 2010;29:10–15.
   PubMed Web of Science ®Google Scholar
• Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther. 2010;23:114–18.
   PubMed Web of Science ®Google Scholar
• Churton S, Brown L, Shin TM, Korman NJ. Does treatment of psoriasis reduce the risk of cardiovascular diseases? Drugs. 2014;74:169–82.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Investig Dermatol. 2009;129:2411–18.
   PubMed Web of Science ®Google Scholar
• Ludwig RJ, Herzog C, Rostock A. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156:271–76.
   PubMed Web of Science ®Google Scholar
• Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829–35.
   PubMed Web of Science ®Google Scholar
• Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31:1000–06.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143:1493–99.
   PubMed Web of Science ®Google Scholar
• Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis in patients but not in outpatients. Eur J Epidemiol. 2004;19:225–30.
   PubMed Web of Science ®Google Scholar
• Lindegard B. Mortality and causes of death among psoriatics. Dermatologica. 1989;179:91–92.
   PubMedGoogle Scholar
• Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108:2957–63.
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74.
   PubMed Web of Science ®Google Scholar
• Carter AM. Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res. 2005;2:113–21.
   PubMedGoogle Scholar
• Kiortsis DN, Mavridis AK, Vasakos S, et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis. 2005;64:765–66.
   PubMed Web of Science ®Google Scholar
• Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis. 2005;64:303–05.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. J Am Med Assoc. 2006;292:1735–41.
   Web of Science ®Google Scholar
• McDonald CJ, Calabresi P. Psoriasis and occlusive vascular disease. Br J Dermatol. 1978;99:469–75.
   PubMed Web of Science ®Google Scholar
• Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, nonsteroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systemic review and meta-analysis. Ann Rheum Dis. 2015;74:480–89.
   PubMed Web of Science ®Google Scholar
• Gulliver W, MacDonald D, Glandney N, et al. Long-term prognosis and comorbidities associated with psoriasis in the Newfoundland and Labrador Founder population. J Cutan Med Surg. 2011;15:37–47.
   PubMed Web of Science ®Google Scholar
• Gulliver W, MacDonald D, Connors S, Cardiovascular diseases and moderate to severe psoriasis: early age of onset linked to 9-fold increased risk of MI; biologic therapy linked to 83% decreased risk of MI. The late-breaking research Dermatology Forum (F025). 73rd Annual Meeting of The American Academy of Dermatology 2015, San Francisco, USA.
   Google Scholar
• Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol. 2006;2:99–106.
   PubMedGoogle Scholar
• Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24:278–301.
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med.2005;352:1685–95.
   PubMed Web of Science ®Google Scholar
• Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003;278:45777–84.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Investig. 1994;94:1543–49.
   PubMed Web of Science ®Google Scholar
• Prodanovich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52:262–67.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148:1244–50.
   PubMed Web of Science ®Google Scholar
• Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1213–18.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Symmons DP. What effects might anti-TNF alpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNF alpha in cardiovascular pathophysiology. Ann Rheum Dis. 2007;66:1132–36.
   PubMed Web of Science ®Google Scholar
• Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:576–82.
   PubMed Web of Science ®Google Scholar
• Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med. 2013;273:197–204.
   PubMed Web of Science ®Google Scholar
• Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol. 2015;29:1128–34.
   PubMed Web of Science ®Google Scholar
• Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol. 2011;165:1066–73.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Liu L, Asgari MM, et al. Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis. J Eur Acad Dermatol Venereol. 2014;28:1380–87.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Rowan CG, Bebchuk JD, Anthony MS. Association between tumor necrosis factor inhibitor (TNFi) therapy and changes in C-reactive protein (CPR), blood pressure, and alanine aminotransferase (ALT) among patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis. J Am Acad Dermatol. 2015;72:917–19.
   PubMed Web of Science ®Google Scholar
• Wu JJ, Rowan CG, Bebchuk JD, Anthony MS. Total cholesterol, lipoprotein, and triglyceride levels in tumour necrosis factor inhibitor-treated patients with psoriasis, psoriatic arthritis or rheumatoid arthritis. Int J Dermatol. 2015;54:e442–45.
   PubMed Web of Science ®Google Scholar